189 related articles for article (PubMed ID: 35303106)
1. Endocrine Autoantibodies Determine Immune Checkpoint Inhibitor-induced Endocrinopathy: A Prospective Study.
Labadzhyan A; Wentzel K; Hamid O; Chow K; Kim S; Piro L; Melmed S
J Clin Endocrinol Metab; 2022 Jun; 107(7):1976-1982. PubMed ID: 35303106
[TBL] [Abstract][Full Text] [Related]
2. Immune checkpoint inhibitor-induced endocrinopathies: a possible indicator of improved survival.
Ornelas M; Borges-Canha M; Gouveia P; Ferreira M; Resende E; Sá M; Abreu S
Arch Endocrinol Metab; 2023 Jun; 67(6):e000654. PubMed ID: 37364153
[TBL] [Abstract][Full Text] [Related]
3. Immune Checkpoint Inhibitors-Induced Endocrinopathies: Assessment, Management and Monitoring in a Comprehensive Cancer Centre.
Elshafie O; Khalil AB; Salman B; Atabani A; Al-Sayegh H
Endocrinol Diabetes Metab; 2024 Jul; 7(4):e00505. PubMed ID: 38932429
[TBL] [Abstract][Full Text] [Related]
4. Thyroid Immune-related Adverse Events Following Immune Checkpoint Inhibitor Treatment.
Muir CA; Clifton-Bligh RJ; Long GV; Scolyer RA; Lo SN; Carlino MS; Tsang VHM; Menzies AM
J Clin Endocrinol Metab; 2021 Aug; 106(9):e3704-e3713. PubMed ID: 33878162
[TBL] [Abstract][Full Text] [Related]
5. Clinical Characteristics, Management, and Potential Biomarkers of Endocrine Dysfunction Induced by Immune Checkpoint Inhibitors.
Iwama S; Kobayashi T; Arima H
Endocrinol Metab (Seoul); 2021 Apr; 36(2):312-321. PubMed ID: 33934588
[TBL] [Abstract][Full Text] [Related]
6. Immune Checkpoint Inhibitor-Associated Primary Adrenal Insufficiency: WHO VigiBase Report Analysis.
Grouthier V; Lebrun-Vignes B; Moey M; Johnson DB; Moslehi JJ; Salem JE; Bachelot A
Oncologist; 2020 Aug; 25(8):696-701. PubMed ID: 32390168
[TBL] [Abstract][Full Text] [Related]
7. Endocrinopathies Associated With Immune Checkpoint Inhibitor Use.
Kotwal A; Kennedy R; Kikani N; Thosani S; Goldner W; Shariff A
Endocr Pract; 2024 Jun; 30(6):584-591. PubMed ID: 38554775
[TBL] [Abstract][Full Text] [Related]
8. The side effects of immune checkpoint inhibitor therapy on the endocrine system.
Goyal I; Pandey MR; Sharma R; Chaudhuri A; Dandona P
Indian J Med Res; 2021 Apr; 154(4):559-570. PubMed ID: 35435341
[TBL] [Abstract][Full Text] [Related]
9. Combined Hypophysitis and Type 1 Diabetes Mellitus Related to Immune Checkpoint Inhibitors.
Fujita Y; Kamitani F; Yamamoto M; Fukuoka H; Hirota Y; Nishiyama N; Goda N; Okada Y; Inaba Y; Nakajima H; Kurematsu Y; Kanie K; Shichi H; Urai S; Suzuki M; Yamamoto N; Bando H; Iguchi G; Suto H; Funakoshi Y; Kiyota N; Takahashi Y; Ogawa W
J Endocr Soc; 2023 Jan; 7(3):bvad002. PubMed ID: 36694808
[TBL] [Abstract][Full Text] [Related]
10. Mapping endocrine toxicity spectrum of immune checkpoint inhibitors: a disproportionality analysis using the WHO adverse drug reaction database, VigiBase.
Bai X; Lin X; Zheng K; Chen X; Wu X; Huang Y; Zhuang Y
Endocrine; 2020 Sep; 69(3):670-681. PubMed ID: 32507965
[TBL] [Abstract][Full Text] [Related]
11. The spectrum, incidence, kinetics and management of endocrinopathies with immune checkpoint inhibitors for metastatic melanoma.
Scott ES; Long GV; Guminski A; Clifton-Bligh RJ; Menzies AM; Tsang VH
Eur J Endocrinol; 2018 Feb; 178(2):173-180. PubMed ID: 29187509
[TBL] [Abstract][Full Text] [Related]
12. Immune checkpoint inhibitor-associated pituitary adverse events: an observational, retrospective, disproportionality study.
Bai X; Chen X; Wu X; Huang Y; Zhuang Y; Chen Y; Feng C; Lin X
J Endocrinol Invest; 2020 Oct; 43(10):1473-1483. PubMed ID: 32239475
[TBL] [Abstract][Full Text] [Related]
13. Presence of autoantibodies in serum does not impact the occurrence of immune checkpoint inhibitor-induced hepatitis in a prospective cohort of cancer patients.
Purde MT; Niederer R; Wagner NB; Diem S; Berner F; Hasan Ali O; Hillmann D; Bergamin I; Joerger M; Risch M; Niederhauser C; Lenz TL; Früh M; Risch L; Semela D; Flatz L
J Cancer Res Clin Oncol; 2022 Mar; 148(3):647-656. PubMed ID: 34874490
[TBL] [Abstract][Full Text] [Related]
14. [Endocrinopathies Associated with Immune Checkpoint Inhibitors].
Santos MJ
Acta Med Port; 2022 Mar; 35(3):209-215. PubMed ID: 35077347
[TBL] [Abstract][Full Text] [Related]
15. Spectrum of immune checkpoint inhibitors-induced endocrinopathies in cancer patients: a scoping review of case reports.
Tan MH; Iyengar R; Mizokami-Stout K; Yentz S; MacEachern MP; Shen LY; Redman B; Gianchandani R
Clin Diabetes Endocrinol; 2019; 5():1. PubMed ID: 30693099
[TBL] [Abstract][Full Text] [Related]
16. Mechanistic insights into immune checkpoint inhibitor-related hypophysitis: a form of paraneoplastic syndrome.
Kanie K; Iguchi G; Bando H; Urai S; Shichi H; Fujita Y; Matsumoto R; Suda K; Yamamoto M; Fukuoka H; Ogawa W; Takahashi Y
Cancer Immunol Immunother; 2021 Dec; 70(12):3669-3677. PubMed ID: 33977343
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of autoantibodies as predictors of treatment response and immune-related adverse events during the treatment with immune checkpoint inhibitors: A prospective longitudinal pan-cancer study.
Barth DA; Stanzer S; Spiegelberg J; Bauernhofer T; Absenger G; Posch F; Lipp R; Halm M; Szkandera J; Balic M; Gerger A; Smolle MA; Hutterer GC; Klec C; Jost PJ; Kargl J; Stradner M; Pichler M
Cancer Med; 2022 Aug; 11(16):3074-3083. PubMed ID: 35297215
[TBL] [Abstract][Full Text] [Related]
18. Isolated adrenocorticotropic hormone deficiency following immune checkpoint inhibitors treatment often occurs in polyglandular endocrinopathies.
Chen H; Zhang L; Zhao L; Li X
BMC Endocr Disord; 2023 Jul; 23(1):139. PubMed ID: 37415148
[TBL] [Abstract][Full Text] [Related]
19. Endocrine toxicity of immune checkpoint inhibitors: a real-world study leveraging US Food and Drug Administration adverse events reporting system.
Zhai Y; Ye X; Hu F; Xu J; Guo X; Zhuang Y; He J
J Immunother Cancer; 2019 Nov; 7(1):286. PubMed ID: 31694698
[TBL] [Abstract][Full Text] [Related]
20. Endocrine-related adverse events associated with immune-checkpoint inhibitors in patients with melanoma.
Kassi E; Angelousi A; Asonitis N; Diamantopoulos P; Anastasopoulou A; Papaxoinis G; Kokkinos M; Giovanopoulos I; Kyriakakis G; Petychaki F; Savelli A; Benopoulou O; Gogas H
Cancer Med; 2019 Nov; 8(15):6585-6594. PubMed ID: 31518074
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
